Giuseppe Cianciolo

Giuseppe Cianciolo

Auto-generated profile, based on publicly available information

Giuseppe Cianciolo

Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
GCGiuseppe Cianciolo
Giuseppe Cianciolo
FTFrancesco Tondolo
Francesco Tondolo
SBSimona Barbuto
Simona Barbuto
Andrea AngeliniAndrea Angelini
Andrea Angelini
FFFrancesca Ferrara
Francesca Ferrara
Mario CozzolinoMario Cozzolino
Mario Cozzolino
Chronic kidney disease mineral and bone disorder may persist after successful kidney transplantation. Persistent hyperparathyroidism has been identified in up to 80% of patients throughout the first year after kidney transplantation. International guidelines lack strict recommendations about the management of persistent hyperparathyroidism. However, it is associated with adverse graft and patient outcomes, including higher fracture risk and an increased risk of all-cause mortality and allograft loss. Secondary hyperparathyroidism may be treated medically (vitamin D, phosphate binders and calcimimetics) or surgically (parathyroidectomy). Guideline recommendations suggest medical therapy first but do not clarify optimal parathyroid hormone targets or indications and timing of parathyroidectomy. There are no clear guidelines or long-term studies about the impact of hyperparathyroidism therapy. Parathyroidectomy is more effective than medical treatment, although it is associated with increased short-term risks. Ideally parathyroidectomy should be performed before kidney transplantation to prevent persistent hyperparathyroidism and improve graft outcomes. We now propose a roadmap for the management of secondary hyperparathyroidism in patients eligible for kidney transplantation that includes the indications and timing (pre- or post-kidney transplantation) of parathyroidectomy, the evaluation of parathyroid gland size and the integration of parathyroid gland size in the decision-making process by a multidisciplinary team of nephrologists, radiologists and surgeons.

9 July 2011 in Blood Purification
Verified
Journal Article
Closed access
GCGiuseppe Cianciolo
Giuseppe Cianciolo
Gaetano La MannaGaetano La Manna
Gaetano La Manna
MCMaria Cappuccilli
Maria Cappuccilli
NLNicole Lanci
Nicole Lanci
EBElena Della Bella
Elena Della Bella
SSSergio Stefoni
Sergio Stefoni
Background/Aims: Vitamin D deficiency is associated with endothelial dysfunction in uremic patients, possibly by the impairment in the number and function of endothelial progenitor cells (EPCs). In 89 hemodialysis patients, we investigated the factors associated with the number of circulating EPCs (CD34+/CD133+/KDR+ and CD34+/CD133–/KDR+ cells), the presence of VDR and the determinants of VDR expression on EPCs, in particular in calcitriol therapy. Methods: EPC counts, percentages of VDR-positive EPCs and VDR expression were assessed by flow cytometry. Cells isolated from a subgroup of patients were cultured to analyze colony-forming units, specific markers expression and a capillary-like structure formation. Results/Conclusions: Our study demonstrates the presence of VDR on EPCs. In our dialysis patients, the parameters studied on both CD34+/CD133+/KDR+ and CD34+/CD133–/KDR+ cells, in particular VDR expression, seem to be influenced by uremia-related factors, including anemia, inflammation, diabetes, 25(OH)D serum levels and calcitriol therapy.

23 February 2000 in Blood Purification
Verified
Journal Article
Closed access
PDF file
LCL. Colì
L. Colì
Mauro UrsinoMauro Ursino
Mauro Ursino
APAntonio De Pascalis
Antonio De Pascalis
CBC. Brighenti
C. Brighenti
VDV. Dalmastri
V. Dalmastri
SSS. Stefoni
S. Stefoni
A mathematical model of solute kinetics for the improvement of hemodialysis treatment is presented. It includes a two-compartment description of the main solutes and a three-compartment model of body fluids (plasma, interstitial and intracellular). The main model parameters can be individually assigned a priori, on the basis of body weight and plasma concentration values measured before beginning the session. Model predictions are compared with clinical data obtained in vivo during 11 different hemodialysis sessions performed on 6 patients with a profiled sodium concentration in the dialysate and a profiled ultrafiltration rate. In all cases, the agreement between the time pattern of model solute concentrations in plasma and the in vivo data proves fairly good as to urea, sodium, chloride, potassium and bicarbonate kinetics. Only in two sessions was blood volume directly measured in the patient, and in both cases the agreement with model predictions was good. In conclusion, the model allows a priori computation of the amount of sodium removed during hemodialysis, and makes it possible to predict the plasma volume changes and plasma osmolarity changes induced by a given sodium concentration profile in the dialysate and by a given ultrafiltration profile. Hence, it can be used to improve clinical tolerance to the dialysis session taking the characteristics of individual patients into account, in order to minimize intradialytic hypotension.

1 August 2003 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
LCL. Colì
L. Colì
Mauro UrsinoMauro Ursino
Mauro Ursino
GDGabriele Donati
Gabriele Donati
GCG. Cianciolo
G. Cianciolo
MSM.L. Soverini
M.L. Soverini
SSS. Stefoni
S. Stefoni
Background: Intradialytic hypotension is mainly induced by the removal of extracellular sodium during dialysis, which impairs intravascular fluid refilling and reduces blood volume. To counter this complication we tested a new kind of profiled hemodialysis (PHD) consisting of the intradialytic modulation of dialysate sodium concentration according to individual profiles set up using a new mathematical model for intradialytic solutes and water kinetics. The clinical aim of this PHD is to stabilize blood pressure maintaining higher blood volume values than standard dialysis treatments. We clinically validated PHD in comparison with constant dialysate sodium dialysis (CHD). Methods: Twenty hypotensive dialysis patients underwent one PHD and one CHD session maintaining the same dialysis length, sodium mass removal and body weight decrease. A new mathematical model was used to define both the dialysate sodium profiles for PHD and the constant dialysate sodium for CHD. Percent blood volume variation (Crit-line), mean blood pressure, heart rate, cardiac output (Doppler-echocardiography) were monitored intradialitically. Results: Cardiovascular stability improved on PHD as compared with CHD sessions; blood volume and cardiac output during PHD showed a lower decrease than on CHD, the differences statistically significant (from 30' and 60' respectively). Mean blood pressure was, at all time intervals, more stable on PHD than on CHD and was accompanied, on PHD, by a lower heart rate increase (differences statistically significant). Conclusions: This study shows that PHD performed using dialysate sodium profiles elaborated by our mathematical model obtains, in hypotensive patients, a higher hemodynamic intradialytic stability than CHD, probably due to a higher stabilization of blood volume.

1 July 2024 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
CACarlo Alfieri
Carlo Alfieri
PMPaolo Molinari
Paolo Molinari
SVSimone Vettoretti
Simone Vettoretti
MFMaria Fusaro
Maria Fusaro
JBJordi Bover
Jordi Bover
GCGiuseppe Castellano
Giuseppe Castellano
Chronic kidney disease (CKD) poses a significant epidemiological challenge, necessitating effective patient management strategies. Nutritional intervention, particularly vitamin D supplementation, has garnered attention for its potential therapeutic utility in CKD. Despite widespread acknowledgment of the importance of vitamin D, particularly in bone and mineral metabolism, its supplementation in CKD patients for non-skeletal purposes remains contentious due to limited evidence. Hypovitaminosis D linked with CKD substantially contributes to disturbances in mineral and bone metabolism, increasing the risks of cardiovascular complications and skeletal disorders. Notably, CKD patients experience progressive vitamin D deficiency, exacerbating as the disease progresses. Guidelines recommend monitoring 25-hydroxyvitamin D (25 (OH)-D) levels due to their correlation with mineral metabolism parameters, although robust evidence for recommending supplementation is lacking. The primary aim of this paper is to focus on the main open questions regarding vitamin D supplementation in CKD, reporting the current evidence concerning the role of vitamin D supplementation in CKD and in renal transplant recipients. Graphical abstract

7 January 2026 in Kidney360
Verified
Journal Article
Open access
APAntonio De Pascalis
Antonio De Pascalis
ATAlessandro Tomassetti
Alessandro Tomassetti
DVDaniele Vetrano
Daniele Vetrano
MIMassimo Iacoviello
Massimo Iacoviello
SMStefania Marazia
Stefania Marazia
GCGiuseppe Cianciolo
Giuseppe Cianciolo
Combined inhibition of neprilysin (NEP) and the angiotensin II receptor through angiotensin receptor–neprilysin inhibitors (ARNIs) has transformed heart failure management and is garnering increasing attention in nephrology. This article explores the renal role of NEP and critically reviews preclinical and clinical evidence on the use of ARNIs in CKD, following a bench-to-bedside approach. Experimental data show that NEP inhibition improves proteinuria, fibrosis, and endothelial function, with enhanced benefits when combined with renin-angiotensin-aldosterone system blockade. Randomized clinical trials in patients with heart failure (HF) (Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor With Angiotensin Converting Enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF], Prospective Comparison Angiotensin Receptor–Neprilysin Inhibitor with Angiotensin-Receptor Blockers Global Outcomes in Heart Failure with Preserved Ejection Fraction [PARAGON-HF], Prospective comparison of Angiotensin Receptor–neprilysin inhibitor with Angiotensin-Receptor Blockers Given following stabiLization In DEcompensated Heart Failure with preserved ejection fraction [PARAGLIDE-HF]) have demonstrated renal safety and potential benefit emerged in secondary end points and prespecified analysis. The only randomized clinical trial performed with primary kidney outcome, the UK Heart and Renal Protection III (HARP-III) trial, confirmed the tolerability of sacubitril/valsartan, and reported a significant reduction in proteinuria. No clear nephroprotective effect was observed; however, the trial design may not have been adequately structured to detect such an effect. On the other hand, real-world data indicate that ARNIs have an acceptable risk profile when patients are appropriately monitored, as renin-angiotensin-aldosterone system blockers. Moreover, the benefits of the treatment clearly outweigh the adverse effects. Therefore, sacubitril/valsartan may emerge as a promising therapeutic option in nephrology, especially in patients with cardiorenal disease, pending further trials to better define its role in CKD.